Compare ONMD & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ONMD | NNVC |
|---|---|---|
| Founded | 2006 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.3M | 33.7M |
| IPO Year | 2021 | 2008 |
| Metric | ONMD | NNVC |
|---|---|---|
| Price | $5.36 | $1.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 25.8K | ★ 157.8K |
| Earning Date | 11-24-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 83.33 | 34.92 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,359,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 111.35 | N/A |
| 52 Week Low | $0.63 | $0.85 |
| 52 Week High | $115.00 | $1.93 |
| Indicator | ONMD | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 41.05 | 47.92 |
| Support Level | $3.86 | $1.24 |
| Resistance Level | $39.25 | $1.49 |
| Average True Range (ATR) | 0.52 | 0.09 |
| MACD | 0.75 | -0.01 |
| Stochastic Oscillator | 59.81 | 33.33 |
OneMedNet Corp is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. It is a provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data(iRWDTM). Its solutions connect healthcare providers and patients, satisfying a crucial need within the life sciences field, offering direct access to clinical images and the associated contextual patient record. Its technology has provens the commercial and regulatory viability of imaging Real World Data, an emerging market, and provides regulatory-grade, image-centric iRWDTM. Geographically, it operates in Americas, Europe and Middle East, and Asia Pacific. It derives maximum revenue from Europe and Middle East.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company is engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific antiviral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing. The Company's platform is based on host-mimicry and thereby has uniquely enabled the development of broad-spectrum antiviral drugs that the viruses would be unable to escape, a critical unmet need in antiviral therapeutics.